This indicated that our findings were agreement with the result of previous studies, which reported that if AML patients had FIT3-ITD or FIT3-ITD combined with a WT1 mutation, their prognosis was poor, while the prognosis was better when there was a CEBPA or NPM1 mutation [57]. The gene discussed is WT1; the disease is acute myeloid leukemia.